Les Laboratoires Servier

Université´de Rouen

Cephalon France

Takeda Pharmaceutical Company Limited

Les Laboratories Servier

Viropharma Incorporated

Quantum Genomics

Produits Chimiques Auxiliaires Et De Synthese

Organisation De Synthese Mondiale Orsymonde

Gerard Coquerel

Julie Linol

Jean-Claude J Souvie

Guillaume Levilain

Marie-Noelle Petit

Laurent Courvoisier

Franck Patrick Mallet

Servane Coste-Leconte

Véronique Broquaire, Legal Representative

Jean-Marie Schneider

Armand Frydman

Pascale Authouart

Ludovic Broquaire, Legal Representative

Loiec Lefebvre

Jean-Pierre Lecouve

Pascal Langlois

Fabrice Balavoine

Jonathan Madec

Olivier Neckebrock

Nicolas Couvrat

Adriaan Jan Van Langevelde

Pierre Leproust

Guillaume Tauvel

Yohann Cartigny

Stephanie Graf

Damien Martins

Lionel Catroux

Anais Lafontaine

Julien Mahieux

Gilles Serrure

Snella Chouippe

Yvette Combret

Morgane Sanselme

Christine Besselievre

Lionel Le Pape

Michel Broquaire

Francois-Xavier Gendron

Sebastien Rose

The invention relates to novel crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole (Maribavir), pharmaceutical compositions thereof and their use in medical therapy.

Crystalline phases of 5,6-dichloro-2-(isopropylamino)-(1 β-L-ribofuranosyl)-1H-benzimidazole

The invention relates to novel crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-(&#x3b2;-L-ribofuranosyl)-1H-benzimidazole (Maribavir), pharmaceutical compositions thereof and their use in medical therapy.

Crystalline phases of 5,6-dichloro-2-(isopropylamino)-(1-beta-L-ribofuranosyl)-1H-benzimidazole

The present invention relates to a new method for the preparation of (3S,3S') 4,4&#x2032;-disulfanediylbis(3-aminobutane 1-sulfonic acid) in five steps from (S)-ethyl 2-(benzyloxycarbonylamino)-4-(neopentyloxysulfonyl)butanoate A.

Method for the preparation of (3S,3S') 4,4&#x2032;-disulfanediylbis (3-aminobutane 1-sulfonic acid)

The present invention relates to a method and a device for measuring scattering of X-rays wherein the compound to be analyzed is installed in a receptacle comprising an X-ray-permeable flat bottom, wherein the X-ray diffraction analysis is undertaken by sending an X-ray stream upwards toward said X-ray-permeable bottom and by measuring the stream of scattered X-rays reflected downwards, and wherein a fluid thermostatically controlled to the same temperature as that of the compound to be analyzed in the receptacle is projected toward the X-ray permeable flat bottom, from outside the receptacle.

Method of measuring scattering of X-rays, its applications and implementation device

A process for the resolution of two enantiomers which involves inducing the preferential crystallization of one enantiomer by adjusting the composition of a suspension or solution including a racemic mixture of the two enantiomers and a solvent, by evaporation of the latter.

Process for the resolution of enantiomers by preferential evaporative crystallization

A precursor phase of the magnesium tetrahydrate salt of an omeprazole enantiomer, and also processes for preparing it and its use for the preparation of the magnesium tetrahydrate salt are described. Crystals of the magnesium tetrahydrate salt thus obtained, and their uses, especially in the synthesis of the dihydrate form A of the magnesium salt of the enantiomer or as medicament are also disclosed.

Precursor phase and use thereof for preparing the magnesium tetrahydrate salt of an omeprazole enantiomer

Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-&#x3b2;-L-ribofuranosyl)-1H-benzimidazole

Process for obtaining the crystalline form V of the compound of formula (I): 

Process for obtaining the crystalline form V of agomelatine

Crystalline form VI of the compound of formula (I): characterised by its X-ray powder diffraction diagram. Medicinal products containing the same which are useful in treating melatoninergic disorders.

Crystalline form VI of agomelatine, a process for its preparation and pharmaceutical compositions containing it

Crystalline form III of the compound of formula (I): characterised by its powder X-ray diffraction diagram. Medicinal products containing the same which are useful in the treatment of melatoninergic disorders.

Crystalline form III of agomelatine, a process for its preparation and pharmaceutical compositions containing it

Crystalline form IV of the compound of formula (I): characterised by its powder X-ray diffraction diagram. Medicinal products containing the same which are useful in the treatment of melatoninergic disorders.

Crystalline form IV of agomelatine, a process for its preparation and pharmaceutical compositions containing it

Polymorphic forms of modafinil racemate, methods of preparation thereof, pharmaceutical compositions and methods of therapeutic treatment involving modafinil polymorphic forms.

Modafinil polymorphic forms

Crystalline form III of the compound of formula (I): characterized by its powder X-ray diffraction diagram. Medicinal products containing the same which are useful in the treatment of melatoninergic disorders.

Modafinil polymorphic forms of modafinil racemate, methods of preparation thereof, pharmaceutical compositions and methods of therapeutic treatment involving modafinil polymorphic forms.

Growing community of inventors

Boos, France

Gerard Coquerel